Trial · NCT06948825
Effectiveness Study of a Lifestyle Intervention Versus Metformin in Mothers With Recent Gestational Diabetes
NCT06948825, Phase 2, Active not recruiting, George Washington University
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Effectiveness Study of a Lifestyle Intervention Versus Metformin in Mothers With Recent Gestational Diabetes. Trials, record NCT06948825. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06948825
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Effectiveness Study of a Lifestyle Intervention Versus Metformin in Mothers With Recent Gestational Diabetes
- NCT number
- NCT06948825
- Status
- Active not recruiting
- Phases
- Phase 2
- Enrollment
- 41 participants, actual
- Lead sponsor
- George Washington University
- Conditions
- Weight Loss, Gestational Diabetes Mellitus in Pregnancy, Postpartum Care
- Interventions
- Metformin Hcl 850Mg Tab, Lifestyle Intervention, Enhanced Lifestyle Intervention
- First posted
- 2025-04-29
- Last updated
- 2026-11-06
Source ClinicalTrials.gov
Registered outcomes12
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Mean weight change at 6 months | 6 months | Weight in kg. |
| Secondary | Change in physical activity | 6 months | Measured using the Paffenberger Physical Activity Questionnaire, scores are calculated as total weekly energy expenditure in kilocalories per week; higher scores indicate better physical activity levels. |
| Secondary | Change in blood pressure | 6 months | Change in blood pressure, measured in mmHg. A better blood pressure reading is considered below 120/80 mmHg. |
| Secondary | Change in A1c | 6 months | Change in A1c lab value, measured in percentage (%), where a better A1c value is below 5.7%. |
| Secondary | Change in lipids | 6 months | Change in lipids, measured in mg/dL, where a better outcome is total cholesterol below 200mg/dL, HDL above 60 mg/dL, LDL below 100 mg/dL, and triglycerides below 150 mg/dL. |
| Secondary | Change in quality of life | 6 months | Measured using the Short-Form Survey 12, where scores range from 0 to 100. Scores higher than 50 indicate better-than-average health. |
| Secondary | Change in depression score | 6 months | Measured using the Edinburgh Postnatal Depression Scale, with scores ranging from 0 to 30, and lower scores indicating better outcomes. A score of 12 or higher indicates the need to connect with a primary care physician or mental health clinician in the GW School of Medicine or the local community. With the participant's permission, the research staff will facilitate this connection. |
| Secondary | Change in diet quality | 6 months | The research team will review participant diet data via the Ascend platform. |
| Secondary | Breastfeeding | 6 months | A question will be asked at the start and end of the study to determine breastfeeding status. |
| Secondary | Adherence to Metformin treatment | 4.5 to 5 months | Participants will complete a Metformin adherence questionnaire every 2 weeks. |
1 to 10 of 12Source ClinicalTrials.gov
See all 12 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers24
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06948825
GET https://conductscience.org/api/trials/v1/NCT06948825/papers?page=2